Notice on Enhancing the Supervision and Management of Outsourced Manufacturing for Drug Marketing Authorization Holders (MAHs) (No. 132, 2023)

Home News Insights

Database

Regulatory Database

Drug Catalog ChP Standards

Events

Webinars Offline Events

Services

Notice on Enhancing the Supervision and Management of Outsourced Manufacturing for Drug Marketing Authorization Holders (MAHs) (No. 132, 2023)

Local Title:国家药监局关于加强药品上市许可持有人委托生产监督管理工作的公告（2023年第132号）
Country/Region:Chinese Mainland
Competent Authority: National Medical Products Administration (NMPA)
Type:Notice
Status:In force
Release Date:2023-10-23
Implementation Date:2023-10-23

Request

Document

Language	Source	Title	Access
ZH	Official	国家药监局关于加强药品上市许可持有人委托生产监督管理工作的公告（2023年第132号）	Download

Summary

The Notice is designed to strengthen the oversight of outsourced manufacturing of drug MAHs, including tightening the authorization of and quality management in outsourced manufacturing.